Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is the leading cause of cancer-related death. Despite advances in chemotherapy and immunotherapy, the prognosis for advanced patients remains poor. The discovery of oncogenic driver mutations, such as anap...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Yan, Zhang, Shiyu, Fang, Xiaoxu, Jiang, Yingying, Fang, Tingwen, Liu, Jinwen, Lu, Kaihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601201/
https://www.ncbi.nlm.nih.gov/pubmed/36290895
http://dx.doi.org/10.3390/curroncol29100618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601201/
https://www.ncbi.nlm.nih.gov/pubmed/36290895
http://dx.doi.org/10.3390/curroncol29100618

Ejemplares similares